DXCM STOCK NOTICE: DexCom, Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 26 Deadline

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud, alleging that the company misled investors about the reliability and accuracy of its continuous glucose monitoring systems, leading to significant stock declines [2][4]. Company Overview - DexCom, Inc. specializes in manufacturing continuous glucose monitoring (CGM) systems, including the Dexcom G6 and G7 models [5]. Allegations and Issues - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7, which compromised the accuracy of the devices and posed potential health risks to customers [6]. - The company allegedly prioritized cost-cutting over safety, ignoring critical safety issues [6]. Stock Performance and Impact - DexCom's stock experienced significant declines due to revelations about quality issues: - On March 7, 2025, the stock fell by $7.12 per share (over 9%) following an FDA warning letter regarding manufacturing concerns [7]. - After the FDA's public disclosure on March 25, 2025, the stock dropped another $3.19 per share (over 4%) [8]. - A report published on September 18, 2025, led to a nearly 12% decline, with the stock dropping $8.99 per share over two trading days [9].